H2 inhalation therapy in patients with moderate COVID-19 (H2COVID): a prospective ascending-dose phase I clinical trial.
Salomez-Ihl C, Giai J, Barbado M, Paris A, Touati S, Alcaraz JP, Tanguy S, Leroy C, Lehmann A, Degano B, Gavard M, Bedouch P, Pavese P, Moreau-Gaudry A, Roustit M, Boucher F, Cinquin P, Brion JP.
Salomez-Ihl C, et al. Among authors: pavese p.
Antimicrob Agents Chemother. 2024 Aug 7;68(8):e0057324. doi: 10.1128/aac.00573-24. Epub 2024 Jul 17.
Antimicrob Agents Chemother. 2024.
PMID: 39016593
Free PMC article.
Clinical Trial.